main content start

Metastatic Prostate Cancer : Standard of care in 2022

How do you like the content?
Prostate Cancer 34m 18s

Metastatic Prostate Cancer : Standard of care in 2022

Conducted on 01 Apr 2022 10:00 am

Professor Nicolas Mottet

Dr.Nicolas Mottet explains the evolution of treatment options for metastatic prostate cancer from ADT alone to addition of Docetaxel , Abiraterone , Enzalutamide & Apalutamide to ADT based on impact of these agents on treatment outcomes & quality of life based on review of data from individual clinical trials . Learn about impact of stratification based on volume of disease and risk categories on treatment outcomes for different agents.

Perks of registering with us
Access to Online/Offline Events
Personalized Content
Access to all Features

Related Webinars

Hi, can I help?
Chat SupportX
Support Team
Hello, how can I help you today?
Please select one of the below options.

Find Information

Unable to Login or Register

Want to share feedback